36 results about "Abnormal proteins" patented technology

A catalytic conformational sensor method for detecting abnormal proteins and proteinaceous particles. The method is based on the interaction of a peptide fragment or probe with an abnormal proteinaceous particle. The interaction catalyzes transformation of the probe to a predominately beta sheet conformation and allows the probe to bind to the abnormal proteinaceous particle. This in turn, catalyzes propagation of a signal associated with the test sample-bound probe. As a result signals can be propagated even from samples containing very low concentrations of abnormal proteinaceous particles. The peptide probes can be designed to bind to a desired peptide sequence or can even be based on dendrimer structure to control further aggregate propagation.

The present invention discloses a substituted quinazoline compound capable of crossing blood-brain barrier, wherein the structure formula of the compound is represented by a formula (I) defined in thespecification. According to the present invention, the substituted quinazoline compound, the derivative and the pharmaceutical salt thereof can unexpectedly cross blood-brain barrier, have the characteristics of drugs used as protein kinase inhibitors, are especially used for medical conditions mediated by the activation mutation forms of epidermal growth factor receptor, and can be used for treating or preventing disorders associated with abnormal protein kinase activity, wherein the disorders comprise cancers, cancer brain metastasis, cancer meningeal metastases, nerve center diseases and the like.

A catalytic conformational sensor method for detecting abnormal proteins and proteinaceous particles. The method is based on the interaction of a peptide fragment or probe with an abnormal proteinaceous particle. The interaction catalyzes transformation of the probe to a predominately beta sheet conformation and allows the probe to bind to the abnormal proteinaceous particle. This in turn, catalyzes propagation of a signal associated with the test sample-bound probe. As a result signals can be propagated even from samples containing very low concentrations of abnormal proteinaceous particles as is the case in many body-fluid derived samples.

The invention provides a multi-target kinase inhibitor, a medicinal composition thereof, and application of the multi-target kinase inhibitor to preparation of medicines for treating diseases caused by abnormal protein kinase activity. The multi-target kinase inhibitor adopts a structural general formula shown as a formula (I). The multi-target kinase inhibitor has an ideal inhibitory effect and specific selectivity, has a great prospect in treating complex heterogeneous diseases and overcoming the medicine resistance.

A compound of formula (I), a pharmaceutically acceptable salt, or hydrate thereof, and a method of preparing the same. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal comprising administering to said mammal a pharmaceutical composition comprising a compound of formula (I).

The presently invention relates to methods, formulations and kits comprising deuterated trehalose for treating myopathies, neurodegenerative disorders, or tauopathies associated abnormal protein aggregation.

It is an object of the present invention to provide an expression vector, a host, a fused protein, a protein, a process for producing a fused protein, and a process for producing a protein, which can prevent formation of an unactive abnormal protein at production of a recombinant protein, and can produce a desired protein as a natural type, that is, a soluble type at a large amount and effectively. That is, the present invention is an expression vector, which comprises: (a) a first coding region encoding a polypeptide having molecular chaperone activity, and (b) a region having at least one restriction enzyme site in which a second coding region encoding a protein can be inserted. In the expression vector of the present invention, the first coding region is operatively linked to a promoter, and the restriction enzyme sites are in the same reading frame as the first coding region, and are downstream of the first coding region, or the restriction enzyme sites are disposed so that the inserted second coding region is operatively linked to a promoter, and the first coding region is in the same reading frame as the second coding region, and is downstream of the second coding region.

A compound of formula (I),a pharmaceutically acceptable salt, or hydrate thereof, and a method of preparing the same. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal comprising administering to said mammal a pharmaceutical composition comprising a compound of formula (I).

A method of detecting a disease associated with abnormal protein aggregation in a subject is provided, the method comprising (a) contacting leukocytes from the subject with a probe that binds to pathogenic protein aggregates, and (b) detecting the probe bound to the pathogenic protein aggregates, wherein the presence of pathogenic protein aggregates in the leukocytes is indicative that the subject has a disease associated with abnormal protein aggregation. In one embodiment, the disease is Alzheimer's disease, mild cognitive impairment or traumatic brain injury.

The invention relates to a cDNA sequence, a coding protein, a full-length gene sequence and the clone method of a 26S proteinase body subunit RPT2 gene (DvRPT2)in Dunaliella viridis. The uplift expression of 26S proteinase body subunit RPT2 gene in Dunaliella viridis enhances the hydrolytic efficient of TP, accelerates that the substrate protein enters the active position of the proteinase body, reduces the abnormal protein content in the cell, and improves the salt resistance of Dunaliella viridis, so the research about Dunaliella viridis RPT2 subunit indicates the protein degradation pathway of 26S proteinase body, the salt endurance mechanism and the salt-resistance plant improvement, which has the finite theoretical and actual application value.

The invention discloses a 5-substituted difluoro piperidine compound capable of penetrating blood brain barrier, wherein the compound has a structural formula represented by a formula (I). According to the present invention, the 5-substituted difluoro piperidine compound, the derivative and the pharmaceutical salt thereof can unexpectedly penetrate blood brain barrier, can have the pharmaceuticalproperties of protein kinase inhibitors, can particularly treat vascular endothelial growth factor receptor 2 or SRC kinase family (FYN)-mediated medical conditions, can further be used for treating or preventing abnormal protein kinase activity related disorders such as cancer, cancer brain metastasis, primary brain cancers such as glioma, malignant glioma, cancer meningeal metastasis, Alzheimer's disease, neurological diseases and the like.

The invention discloses a nasal cavity nano autophagy inducer for preventing and treating early neurodegenerative diseases and a preparation method thereof. The inducer comprises a hydrophobic small molecule having an autophagy induction effect and an amphiphilic surfactant; firstly, a good solvent solution is arranged, a self-carrying carrier-free nanoparticle suspension emulsion is prepared by areprecipitation method, and is freeze-dried to prepare lyophilized powder; before use, the lyophilized powder is resuspended in isotonic physiological saline to obtain the nasal cavity nano autophagyinducer. The nasal cavity nano autophagy inducer can be absorbed through mucosa of an olfactory region by nasal cavity administration, firstly reach and be enriched in olfactory-related regions of abrain, have a special relief effect for common symptom dysosmia of the early neurodegenerative diseases, have a significant clearing effect on abnormal protein aggregation in the olfactory regions andother lesion regions, and be of importance for preventing the further deterioration of the early neurodegenerative diseases such as AD, PD and the like. The inducer has no carrier, no biodegradationproblem and accumulation toxicity, and the drug loading rate is as high as 25% or more.

Alkoxy indolinone based acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.

The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against c-Met and are useful in treating disorders related to abnormal protein kinase activities such as cancer.

Amino acid derivatives of pyrrolyl-indolinones and their amide or ester derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.

This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and / or treating diseases and tumours associated with abnormal protein tyrosine kinase.

The present disclosure relates to a diagnostic kit capable of accurately diagnosing diseases or disorders related with abnormal aggregation or misfolding of proteins, including disorders or diseases caused by aggregation of β-amyloid such as Alzheimer's disease as well as disorders or diseases caused by aggregation of other proteins, based on concentration analysis of the aggregated proteins before and after dissociation.

Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates.

Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose. Also disclosed is an injectable aqueous pharmaceutical formulation comprising a therapeutically effective amount of trehalose.

A method of detecting a disease associated with abnormal protein aggregation in an individual is provided, the method comprising (a) contacting leukocytes from the individual with a probe that binds to a disease-causing protein aggregate, and (b) detecting A probe for a disease-causing protein aggregate, wherein the presence of a disease-causing protein aggregate in the leukocytes indicates that the individual has a disease associated with abnormal protein aggregation. In one embodiment, the disease is Alzheimer's disease, mild cognitive impairment, or traumatic brain injury.

Disclosed are compositions and methods for inhibiting abnormal protein accumulation, promoting motor neuron survival, inhibiting motor neuron degeneration and treating neurodegenerative conditions through expression of a nucleic acid sequence encoding cyclin F in motor neurons with an abnormally low level or activity of cyclin F. Also disclosed are methods for identifying agents that promote survival of motor neurons, inhibit degeneration of motor neurons and / or inhibit abnormal protein accumulation in motor neurons, identifying agents that are useful for treating neurodegenerative conditions, diagnosing neurodegenerative conditions, predicting the progression of neurodegenerative conditions, and monitoring the effectiveness of a therapy in reducing the progression of a neurodegenerative condition.

The invention provides a spirotricyclic compound as shown in formula (I), and simultaneously discloses a preparation method of the compound and application thereof, as well as a pharmaceutical composition containing the spirotricyclic compound. Being an inhibitor of protein kinase, the compound in the invention can be used to treat diseases caused by abnormal protein kinase activity, such as tumors and the like.

The invention relates to a heterocyclic compound for treating Alzheimer disease and a preparation method thereof. The heterocyclic compound has a good effect of inhibiting the activity of acetyl cholinesterase; as proved by a behavioral experiment research of a senescence-accelerated mouse (SAM-P / 8), the heterocyclic compound can effectively improve the memory function of the SAM-P / 8 mouse, so that the heterocyclic compound can be used for treating cognitive dysfunction and / or neural degeneration dementia with abnormal protein aggregation, particularly the Alzheimer disease.

The invention discloses a composition for treating sinergasilliasis. The composition is prepared from the following raw materials in parts by weight: 6-18 parts of melia azedarach leaves, 4-15 parts of Lysima chiaauriculata Hemsl., 6-18 parts of acorus calamus rhizome, 4-15 parts of fimbriae orostachys, 4-15 parts of psidium guajave bark, 2-10 parts of Japanese peristrophe herb, 3-8 parts of porphyra roots, 2-10 parts of semen raphani, 6 to 18 parts of camphor tree leaves, 3-8 parts of rhizoma curculiginis, 4-15 parts of radix trichosanthis, 2-10 parts of yunnanensis balls, 3-8 parts of blacknightshade herb, 2-10 parts of mugwort and the like. The composition, provided by the invention, is short in treatment time, high in cure rate, has no toxic and / or side effects, fast in absorption andhigh in utilization rate, has the functions of repairing and enhancing the body immunity, rapidly cleaning out abnormal protein molecules, and reducing the sensitivity of normal cells to harmful substances, can repair damaged parts or attacked tissues of a body, has the effects of resisting virus invasion and killing parasites, and has an exact curative effect on the sinergasilliasis of fish.

This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and / or treating diseases and tumors associated with abnormal protein tyrosine kinase.

A method of treating and preventing a neurological disorder, such as Alzheimer's disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency (preferably ≈300-3,000 MHz) for a predetermined absorption period (preferably greater than ≈3 days). Each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule for a predetermined treatment period. The EMF can have a specific absorption rate up to about 8 W / kg. The methodology enhances cognition in the subject and / or treats / prevents the underlying neurological disorder or a symptom thereof.

The present invention relates to a method for diagnosing a disease using an analysis of oligomer of an abnormal aggregated protein includes: (1) preparing a body fluid sample including at least one of blood, blood plasma, blood serum, saliva, urine, tear, and mucus; (2) making a dilution of the body fluid sample; (3) using a biosensor to measure and detect an aggregated protein in the diluted body fluid sample; (4) analyzing a signal change of the biosensor caused by the dilution of the aggregated protein to determine a slope according to the dilution from the measurements; and (5) analyzing a proportion of the oligomer from the slope according to the dilution to make a diagnosis. The method uses a biosensor to measure the impedance and the protein concentration of blood and detects the slope according to the numerical value of the monomer and the oligomer to diagnose normal or abnormal protein aggregation or the associated diseases with more accuracy.